

Ajanta House, Charkop, Kandivli West, Mumbai 400 067 India

F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

T +91 22 6606 1000

6th October, 2015

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001

National Stock Exchange of India, Exchange Plaza, 5<sup>th</sup> Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Dear Sir,

Re: Compliance with Clause 49 of the Listing Agreement Scrip Code: BSE - AJANTPHARM 532331 NSE - AJANTPHARM EQ

Pursuant to Clause 49 of the Listing Agreement, enclosed please find the Quarterly Compliance Report for the quarter ended on  $30^{\rm th}$  September, 2015.

Kindly acknowledge receipt.

Thanking You,

Yours faithfully, for AJANTA PHARMA LIMITED

GAURANG SHAH Sr. G.M. - Legal & Company Secretary

Encl.: a/a

Format of Quarterly Compliance Report on Corporate Governance Name of the Company : Ajanta Pharma Limited Quarter ending on : 30<sup>th</sup> September, 2015

Particulars	Clause of Listing Agreement	Compliance Status Yes/No	Remarks
II. Board of Directors	49 (II)		
(A) Composition of Board	49(IIA)	Yes	
(B) Independent Directors	49(IIIB)	Yes	
(C) Non-executive Directors' Compensation & Disclosures		Yes	
(D) Other Provisions as to Board and Committees	49 (IID)	Yes	
(E) Code of Conduct	(49 (IIE)	Yes	
(F) Whistle Blower Policy	49(IIF)	Yes	Placed on intranet as it is concerning Directors and employees only
III. Audit Committee	49 (III)		
(A) Qualified & Independent Audit Committee	49 (IIIA)	Yes	
(B) Meeting of Audit Committee	49 (IIIB)	Yes	
(C) Powers of Audit Committee	49 (IIIC)	Yes	
(D) Role of Audit Committee	49 (IIID)	Yes	
(E) Review of Information by Audit Committee	49 (IIIE)	Yes	
IV. Nomination and Remuneration Committee	49(IV)	Yes	
V. Subsidiary Companies	49 (V)	Yes	
VI. Risk management	49(VI)	Yes	
VII. Related Party Transactions	49(VII)	Yes	
VIII. Disclosures	49 (VIII)		
(A) Related Party Transactions	49 (VIIIÁ)	Yes	The company does not have any material related party transactions which are to be disclosed
(B) Disclosure of Accounting Treatment	49 (VIIIB)	N.A.	
(C) Remuneration of Directors	49 (VIIIC)	Yes	Has been disclosed in the Annual Report
(D) Management	49 (VIIID)	Yes	Has been disclosed in the Annual Report
(E) Shareholders	49 (VIIIE)	Yes	Has been disclosed in the Annual Report
(F) Proceeds from Public Issues, Rights Issues, Preferential Issues etc.	49 (VIIIF)	N.A.	
IX, CEO/CFO Certification	49 (IX)	Yes	
X. Report on Corporate Governance	49 (X)	Yes	Has been disclosed in the Annual Report
XI. Compliance	49 (XI)	Yes	Has been disclosed in the Annual Report

For AJANTA PHARMA LIMITED

GAURANG SHAH

Sr. G.M. - Legal & Company Secretary